This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fisher, M. Articles by Zipser, R. Search for Related Content PubMed PubMed Citation Articles by Fisher, M. Articles by Zipser, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Stroke, Vol 16, 10-14, Copyright © 1985 by American Heart Association

ARTICLES

Increased excretion of immunoreactive thromboxane B2 in cerebral ischemia

M Fisher and R Zipser

Thromboxane B2 (TXB2) is the stable metabolite of thromboxane A2 (TXA2), a potent vasoconstrictor which induces irreversible platelet aggregation. The inhibition of TXA2 by aspirin and other agents has been associated with improved outcome following cerebral ischemia in clinical and laboratory studies. To investigate the relation of TXA2 production to cerebral ischemia, we measured the urinary excretion of TXA2 metabolites in 30 patients with acute cerebral ischemia. Urinary immunoreactive TXB2 for this group of ischemic patients was elevated compared to normals, 1818 +/- 344 pg/mg Cr (mean +/- SE) vs 880 +/- 122 pg/mg Cr (p less than .05). Among various subsets of the ischemic patients, those with severe stroke (2108 +/- 536 pg/mg Cr), large vessel disease (1646 +/- 335 pg/mg Cr), and cardiogenic stroke (2712 +/- 1045 pg/mg Cr) were all significantly elevated. Of the stroke patients, only the males demonstrated this significant elevation. These elevations of urinary immunoreactive TXB2 are consistent with a role for increased platelet activation in the pathogenesis of some forms of cerebral ischemia and suggest that gender differences in arachidonate metabolism may exist for stroke patients.

This article has been cited by other articles:

				S. Kamath, A.D. Blann, and G.Y.H. Lip Platelet activation: assessment and quantification Eur. Heart J., September 1, 2001; 22(17): 1561 - 1571. [PDF]

				N. M Smith, R. Pathansali, and P. M. Bath Platelets and stroke Vascular Medicine, August 1, 1999; 4(3): 165 - 172. [Abstract] [PDF]

				G. R. Thomas, H. Thibodeaux, C. J. Errett, M. M. Bednar, C. E. Gross, and W. F. Bennett Intravenous Aspirin Causes a Paradoxical Attenuation of Cerebrovascular Thrombolysis Stroke, June 1, 1995; 26(6): 1039 - 1046. [Abstract] [Full Text]